The Valley Desk

ArticleThe Journal of investigative dermatologyPublished

A Phase 2, Randomized, Placebo-Controlled Study of Bermekimab in Moderate-to-Severe Hidradenitis Suppurativa

Read the publication ↗

Regional connection

Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

Publication record

Type
Article
Venue
The Journal of investigative dermatology
Published
Subject terms
Safety; efficacy; Hidradenitis Suppurativa; Bermekimab; Hidradenitis Suppurativa Clinical Response
PubMed ID
40865678
Added to directory
Source checked

Report a correction or request removal